Form 4: Teva Pharmaceutical Industries Director Roberto Mignone Sells 519,000 Shares

Director Roberto Mignone sold 519,000 ordinary shares of Teva Pharmaceutical Industries at a weighted average price of $17.03, while also correcting previous filings regarding direct ownership.

Summary

• Roberto Mignone, a director of Teva Pharmaceutical Industries, sold 519,000 ordinary shares on June 18, 2024, at a weighted average price of $17.03.
• The shares were sold in multiple transactions with prices ranging from $16.96 to $17.16.
• Mignone also indirectly owns 981,000 ordinary shares through Swiftcurrent Master Fund, Ltd., where Bridger Management, LLC acts as the investment advisor and Mignone is the manager.
• The filing corrects an overstatement in previous Form 4 filings from August 7, 2023, and June 17, 2024, regarding the number of directly owned shares.
• The corrected direct ownership after prior transactions should have been 74,575 shares and 95,683 shares, respectively.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the director's share sale, which could be interpreted as a lack of confidence. However, the correction of previous filings adds a layer of uncertainty.

Negatives

• A director selling a significant number of shares could be perceived negatively by the market.

Risks

• The sale of shares by a director could indicate a lack of confidence in the company's future performance.
• The correction of previous filings may raise questions about the accuracy of past disclosures.

Industry Context

Director share sales are common and can be for various reasons, including personal financial planning. However, large sales can sometimes be interpreted as a lack of confidence in the company's prospects, especially in the volatile pharmaceutical industry.

Comparison to Industry Standards

• Comparing Mignone's transactions to those of other directors in similar pharmaceutical companies would provide a better understanding of whether this sale is typical or unusual.
• Analyzing the timing of the sale relative to Teva's stock performance and industry trends can offer additional context.
• Benchmarking against insider trading policies and practices of comparable firms can help assess the appropriateness of the transaction.

Stakeholder Impact

• Shareholders may react to the director's share sale, potentially impacting the stock price.
• The correction of previous filings could affect investor confidence.

Key Dates